Nasal Exosomes: Significantly Enhance Cognitive Function

Exosomes represent a new frontier in regenerative medicine, aiding disease treatment and promoting healthy longevity.

Literature indicates that nasal drop-derived stem cell secretome is a safe, simple treatment that can be administered at home.

From the perspective of improving cognitive function, this approach could become a new therapy for treating cognitive impairment in Alzheimer's disease.

A clinical trial involving 13 patients with Alzheimer's disease showed that intranasal administration of mesenchymal stem cell-derived exosomes for 8 weeks was safe and resulted in a significant increase in Hasegawa Dementia Scale-Revised (HDS-R) scores.

Neurocognitive disorders are a major impediment to healthy longevity. As societies age, research into these disorders is deepening; Alzheimer's disease (AD) is the primary cause of cognitive impairment.

Alzheimer's disease is a common neurodegenerative disorder that significantly impairs cognitive function and quality of life. While multiple drugs are currently available to treat Alzheimer's, most can only slow symptom progression without addressing the root cause.

In recent years, stem cell therapy has emerged as a research hotspot, with applications of stem cell-derived exosomes offering new hope for Alzheimer's disease treatment. Increasing clinical evidence suggests that intranasal administration of stem cell exosomes could become a promising new option for Alzheimer's care. Exosome-based therapy represents a cutting-edge frontier in regenerative medicine, contributing to both disease management and healthy longevity.

Recently, a study investigated the safety and clinical efficacy of intranasal administration of stem cell-derived exosomes for treating Alzheimer's disease. The researchers concluded that intranasal delivery of mesenchymal stem cell exosomes over 8 weeks was safe and resulted in a significant increase in Hasegawa Dementia Scale-Revised (HDS-R) scores. Nasal drops of stem cell-secreted exosomes represent a safe, simple treatment that can be administered at home. Given their potential to improve cognitive function, this approach may offer a new therapeutic option for cognitive impairment in Alzheimer's disease.

Clinical Protocol: Intranasal stem cell exosomes, 3 times per week for 8 weeks.

Ingredients: Lyophilized powder of mesenchymal stem cell exosomes with an exosome content of 1 × 10^8, containing HGF (hepatocyte growth factor), one of the primary growth factors.

Content: 1.2 × 10² pg, containing multiple high-concentration bioactive substances such as growth factors and neurotrophic factors.

Patient Profile: The research team selected 13 patients with Alzheimer's disease.

Route of administration: Intranasal administration of mesenchymal stem cell-derived exosomes, 3 times per week for 8 weeks.

Evaluation Metrics: Before and after the study, participants underwent multiple assessments including HDS-R scoring, blood tests, hormone level measurements, and MCI screening.

Clinical Study Results: Nasal Drop Mesenchymal Stem Cell Exosomes Significantly Improve Cognitive Function The research team assessed patients' cognitive function using the Hasegawa Dementia Scale-Revised (HDS-R). After 8 weeks of treatment, patients' HDS-R scores increased from 15.6 to 17.5, indicating significant cognitive improvement. This effect was particularly pronounced in patients with mild to moderate conditions, where scores rose from 17.2 to 20.0. Additionally, blood tests revealed a decrease in platelet count, an increase in the albumin/globulin ratio, and a reduction in the LDL/HDL ratio. These changes may be attributed to the exosomes' regulatory effects on metabolism. MCI screening also showed a significant increase in apolipoprotein A-1 (ApoA1) levels associated with Alzheimer's disease. ApoA1 is known to inhibit the aggregation and toxicity of β-amyloid (Aβ), thereby improving cognitive function.

Clinical Study Results: Nasal Drop Stem Cell Exosomes Are Safe In terms of safety, no treatment-related serious adverse events were observed in 13 patients throughout the entire treatment. Nasal administration of stem cell exosomes demonstrated a favorable safety profile and significantly improved patients' quality of life.

The advantages and potential of stem cell exosome nasal drops continue to be validated. Stem cell exosomes are tiny vesicles secreted by stem cells, containing various bioactive substances such as growth factors, cytokines, and microRNAs. These molecules regulate intercellular communication and promote tissue repair and regeneration. Compared with traditional stem cell therapies, stem cell exosome therapy offers the following advantages:

1. High safety: Exosomes contain no living cells, eliminating the risk of immune rejection and tumor formation.

2. Easy to store and transport: Exosomes can be frozen for long-term storage and convenient shipping over long distances.

3. Multiple Administration Routes: Exosomes can be delivered intravenously, subcutaneously, or via the nasal route, offering convenient administration. Nasal delivery is a non-invasive method that enables rapid drug absorption through the nasal mucosa, bypassing the blood-brain barrier to directly target the brain. For central nervous system disorders such as Alzheimer's disease, nasal delivery offers distinct advantages.

In recent years, an increasing number of research teams have explored the clinical potential of stem cell exosome nasal drops. Last year, a Chinese research team also released clinical data on mesenchymal stem cell exosome nasal spray for treating Alzheimer's disease. This clinical trial not only confirmed the safety of the treatment but also demonstrated that participants tolerated the twice-weekly intranasal dosing regimen, providing key guidance for dose selection in future trials.

The clinical trial data above are encouraging. These results demonstrate that intranasal administration of stem cell-derived exosomes is not only safe but also significantly improves cognitive function in patients with Alzheimer's disease.

In the future, as more large-scale clinical trials are conducted, stem cell-derived exosomes are expected to become a new treatment for Alzheimer's disease.

However, stem cell exosome therapy still faces challenges such as standardized production and long-term safety assessment.

Additionally, selecting appropriate patient populations and optimizing dosing regimens are key areas for future research.

We look forward to more clinical data to advance this therapy and benefit the broader Alzheimer's community.